I-124 PET Imaging and Thyroid Dosimetry

I-124 is a long-lived positron-emitting radioiodine that lets PET/CT measure iodine uptake and project the absorbed dose to thyroid cancer lesions before I-131 therapy. Because all iodine isotopes share the same biochemistry, an I-124 tracer study predicts how a therapeutic I-131 activity will localize — but only if the scanner is calibrated for I-124's unusual decay scheme and the quantification is corrected for its prompt gamma emissions.¹²⁷

Iodine-124 sits at an interesting intersection of imaging and therapy. It is a diagnostic tracer imaged on a standard PET/CT scanner, yet its clinical value is almost entirely in the service of a therapy — patient-specific radioiodine treatment of differentiated thyroid cancer (DTC). That makes I-124 a genuinely quantitative problem: a lesion SUV that is merely "hot" is not enough; the absorbed dose projection that guides I-131 activity depends on accurate, reproducible activity concentrations measured over several days.⁷

This article walks through the decay physics that make I-124 both useful and difficult, the specific quantification pitfalls a physicist must correct, how a lesion-dosimetry protocol is built, and the regulatory context for handling I-124 as byproduct material. DRPS supports PET/CT and nuclear medicine programs across Florida, Maryland, Virginia, Washington DC, California, and Nevada through its PET/CT and nuclear medicine physics and medical physics consulting services.

Introduction

The central idea behind I-124 imaging is theranostic substitution: image with one isotope of an element to predict the behavior of a therapeutic isotope of the same element. I-131, the workhorse of thyroid cancer therapy, emits a 364 keV gamma that can be imaged on a gamma camera, but its images are relatively coarse and its high-energy beta and gamma emissions complicate quantification and add patient dose. I-124, by contrast, is a positron emitter, so it can be imaged with the superior spatial resolution and intrinsic quantitative capability of PET/CT.⁴⁷

Historically, radioiodine therapy of thyroid cancer — the first successful systemic radionuclide therapy — has been delivered with fixed empiric activities, not with dosimetry.⁷ I-124 PET/CT changed what is possible: it currently provides the most accurate non-invasive estimate of absorbed dose to thyroid cancer lesions, letting a physicist tailor the therapeutic I-131 activity to a lesion-dose target rather than a one-size-fits-all prescription.⁷

The catch is physics. I-124 has a "difficult" decay scheme, and treating it like F-18 will produce quantitatively wrong images. Understanding why is the foundation of a defensible I-124 program.

Topic Explanation

What I-124 is, and why its decay scheme matters

I-124 decays with a physical half-life of about 4.18 days (roughly 100 hours) by a combination of electron capture and positron (β⁺) emission.¹³ Two features of that decay dominate everything else:

A low positron branch. Only about 22–23% of I-124 decays produce a positron — compared with roughly 97% for F-18.¹³ Fewer positrons per becquerel means fewer true annihilation coincidences, so I-124 images are inherently count-poor and noisier for a given activity and scan time.
Abundant, high-energy prompt gamma rays. I-124's decay releases numerous gamma rays, the most important being the 603 keV line emitted in roughly 63% of decays, along with lines near 723 keV and 1691 keV.¹³ Some of these prompt gammas are emitted essentially simultaneously with a positron, so they can be detected in coincidence with a genuine 511 keV annihilation photon.

Add to this a high positron endpoint energy — up to about 2.1 MeV — which gives I-124 positrons a longer range in tissue before annihilation than F-18 positrons.³ Longer positron range blurs the reconstructed image because the annihilation, not the decay, is what PET localizes.

The long half-life, which complicates radiopharmacy logistics and adds patient dose, is also precisely what makes multi-day lesion dosimetry feasible — you can follow uptake and clearance over four to five days on the same tracer administration.⁶⁷

The theranostic pairing with I-131

For background on the therapeutic side of this pairing, see our companion posts on I-131 differentiated thyroid cancer therapy and thyroid uptake measurement. The essential point is that I-124 and I-131 are chemically identical: sodium iodide labeled with either isotope is trapped and organified by thyroid tissue by the same sodium-iodide symporter mechanism. An I-124 PET/CT therefore images the same distribution a subsequent I-131 therapy will follow, which is the biological basis for using I-124 uptake to predict I-131 dose.⁴⁷

Key Technical Principles

Comparing I-124 with the isotopes it sits between

Property	I-124	F-18	I-131
Physical half-life	~4.18 days	~110 minutes	~8.02 days
Decay mode	EC + β⁺	β⁺ (dominant)	β⁻
Positron branching	~22–23%	~97%	none
Positron endpoint energy	up to ~2.1 MeV	~0.63 MeV	not applicable
Principal imaging signal	511 keV annihilation (+ 603 keV prompt γ)	511 keV annihilation	364 keV γ
Imaging modality	PET/CT	PET/CT	gamma camera / SPECT
Dominant quantification challenge	prompt-gamma coincidences + positron range	reference case	high-energy γ, septal penetration

The table makes the trade-off explicit. I-124 buys PET-grade resolution and quantitation for iodine imaging, but it pays for it with a count-poor, prompt-gamma-contaminated signal and a wider positron range than the F-18 case most scanner calibrations assume.²³⁷

Prompt gamma (cascade) coincidence contamination

The signature I-124 artifact is the spurious coincidence: a 511 keV annihilation photon detected at the same instant as a 603 keV (or other) prompt gamma from the same decay, or from a nearby decay. The scanner cannot tell that one of the two detected photons is not an annihilation photon, so it assigns a line of response that does not correspond to a real positron annihilation.³

The practical consequence is a roughly uniform additive background across the field of view. In phantom studies, regions that contain no activity ("cold" rods) show apparent positive activity, and the effect is larger in fully 3D acquisition than in 2D (septa-in) acquisition because 3D accepts more scattered and random events.³ Left uncorrected, this background:

inflates apparent activity in low-uptake regions,
reduces lesion-to-background contrast, and
biases the absolute activity concentration that lesion dosimetry depends on.

Correction strategies range from a simple, empirically tuned background subtraction — Herzog and colleagues found that subtracting about 75% of the estimated background minimized the error in non-radioactive phantom regions — to model-based scatter-and-prompt-gamma corrections implemented by the scanner vendor.³ The key QA principle is that the correction must be validated with an I-124 source, not inherited from an F-18 workflow.

Positron range and spatial resolution

Because PET localizes the annihilation point rather than the decay point, a longer positron range degrades spatial resolution. I-124's high positron endpoint energy makes its range longer than F-18's — yet the measured penalty is modest. In classic phantom work on a BGO scanner, I-124 spatial resolution was 13.5 mm FWHM versus 12 mm FWHM for F-18 on the same system: degraded, but not dramatically.² Modern scanners with time-of-flight and point-spread-function modeling narrow this gap further, and the count-poor statistics of the low positron branch are usually a larger practical limitation than positron range alone.²⁵

Worked example: the physics that makes multi-day dosimetry work

The decay constant of I-124 follows directly from its half-life. Using $T_{1/2} \approx 100.3$ hours:

λ = \frac{ln 2}{T _{1/2}} = \frac{0.693}{100.3 h} = 6.91 \times 1 0^{- 3} h^{- 1}

Suppose a lesion is imaged at 24 hours and again at 120 hours after tracer administration (a 96-hour interval). The physical decay factor over that interval is:

\frac{A ( t )}{A _{0}} = e^{- λ t} = e^{- (6.91 \times 1 0^{- 3}) (96)} = e^{- 0.664} = 0.515

So about 52% of the I-124 remains from physical decay alone at the late scan — enough signal to measure clearance while still separating physical decay from biological washout. This is why the ~4.2-day half-life is an asset for dosimetry: a shorter-lived tracer would have decayed away before the biological clearance curve could be sampled.⁶⁷

Lesion absorbed dose is then estimated with the MIRD formalism. The mean absorbed dose to a lesion is the product of the cumulated activity (the time-integrated activity, or area under the time-activity curve) and a lesion S-value:

\overset{ˉ}{D} = \tilde{A} \cdot S, \tilde{A} = \int_{0}^{\infty} A (t) d t

The I-124 PET measures $A (t)$ at each time point; the physicist fits the time-activity curve, integrates it to get $\tilde{A}$ , and projects the I-131 absorbed dose per unit administered activity. For more on the internal-dosimetry framework, see radiopharmaceutical dosimetry and the ICRP 128 framework.

Clinical Impact

From "how hot" to "how much dose"

The clinical payoff of I-124 is that it converts a qualitative uptake question into a quantitative dose question. Serial I-124 PET/CT scans define, for each lesion, both a volume (from the co-registered CT and PET segmentation) and a time-activity curve. Together these let a physicist project the absorbed dose the lesion would receive per gigabecquerel of administered I-131, and therefore choose an I-131 activity aimed at a lesion-dose target.⁷

Published phantom and patient work supports the accuracy needed for this. Wierts and colleagues found that I-124 lesion activity concentrations measured on PET/MRI agreed with PET/CT within about 15% in segmented volume and 25% in concentration, with excellent correlation, and reported an I-124 calibration factor of 0.88 versus 1.00 for F-18 on the same system — a concrete reminder that I-124 needs its own calibration.⁵ Jentzen and colleagues, imaging neck lesions with roughly 25 MBq of I-124 at 24 and 120 hours, achieved activity-concentration agreement within about ±14% for lesions above ~1 kBq/mL — quantification good enough for pre-therapy dosimetry planning.⁶

Staging and lesion detection

Beyond dosimetry, I-124 PET/CT's resolution advantage over I-131 gamma imaging improves detection of metastatic and recurrent disease and supports metabolic tumor-volume measurement, helping separate lower-risk from higher-risk patients.⁴ The same partial-volume and recovery-coefficient effects that limit any PET quantification apply here — small lesions are underestimated unless recovery corrections are applied, a topic we cover in the PET partial volume effect.

Practical Optimization Tips

A defensible I-124 program depends on a handful of disciplined steps.

1. Calibrate for I-124, not F-18

Verify the scanner calibration factor with an I-124 source and cross-check the source activity against your dose calibrator's I-124 setting. Do not assume the F-18 calibration transfers; published data show a difference on the order of 10%.⁵

2. Validate the prompt-gamma correction

Scan a phantom with cold and hot compartments and confirm that the reconstruction's scatter and prompt-gamma corrections drive apparent activity in the cold region close to zero. If the vendor correction is unavailable, characterize an empirical background subtraction and document it.³

3. Standardize acquisition and reconstruction

Because I-124 is count-poor, lengthen acquisition time relative to an F-18 study to recover statistics, and freeze reconstruction parameters (iterations, subsets, filter, PSF, TOF settings) across all time points so serial scans are comparable.²⁶

4. Control the time points

Fix the imaging schedule (for example, near 24 hours and near 96–120 hours) and record injection and scan times precisely; the dosimetry integral is only as good as the sampled time-activity curve.⁶⁷

5. Apply recovery/partial-volume corrections

Use phantom-derived recovery coefficients matched to lesion size and your reconstruction, so small-lesion activity is not systematically underestimated.⁵

Common pitfalls to avoid

Reading I-124 SUVs as if they were F-18 SUVs. Different calibration, different corrections, different meaning.
Ignoring the prompt-gamma background. It quietly biases every low-uptake region and every dosimetry integral.
Changing reconstruction between time points. It destroys the comparability the time-activity curve depends on.
Under-counting. Using F-18-length acquisitions leaves I-124 images too noisy for reliable quantification.
Skipping the dose-calibrator cross-check. An unverified activity assay propagates directly into the projected therapy dose.

Regulatory Considerations

I-124 is byproduct material, and its clinical use is governed by NRC or Agreement State regulations. Diagnostic use of I-124 falls under the medical-use framework of 10 CFR Part 35, and all handling is subject to the radiation protection standards of 10 CFR Part 20.⁸ Because I-124 is often used as the diagnostic half of a radioiodine theranostic pathway, its program should be coordinated with the I-131 therapy program's written directives, patient-release, and radiation-safety procedures where applicable.

Key frameworks to reference:

10 CFR Part 35 — Medical Use of Byproduct Material, which governs authorized users, radiopharmaceutical handling, dosage determination, and the radiation safety officer's responsibilities.⁸
ICRP Publication 107 — Nuclear Decay Data for Dosimetric Calculations, the canonical source for I-124 emission data used in both quantification and dose calculation.¹
NEMA NU 2 — Performance Measurements of Positron Emission Tomographs, the standard governing the scanner-performance characterization (sensitivity, resolution, count-rate) that underlies any quantitative claim.⁹

Jurisdiction matters. Of the states DRPS serves, Florida, Maryland, Virginia, California, Nevada, Pennsylvania, New York, and New Jersey are NRC Agreement States that license medical use of byproduct material under their own radiation-control programs, while Washington DC and Delaware are regulated directly by the NRC. A facility must confirm which authority issues its license and which dosage-determination and recordkeeping requirements apply. For related nuclear-medicine QA context, see PET/CT NEMA NU-2 performance testing.

Frequently Asked Questions (FAQs)

What is I-124 used for in nuclear medicine?

I-124 is a positron-emitting radioiodine used with PET/CT to image radioiodine biodistribution and to estimate the radiation absorbed dose to thyroid cancer lesions before I-131 therapy. Because iodine chemistry is shared across isotopes, I-124 uptake predicts how a therapeutic I-131 dose will behave in the same lesions.

Why is I-124 harder to quantify than F-18?

I-124 emits a positron in only about 22 to 23 percent of decays, so images are count-poor, and it releases high-energy prompt gamma rays that can be detected in coincidence with an annihilation photon. These spurious coincidences add a background that must be corrected, and the high positron energy widens the positron range and slightly degrades spatial resolution.

How does I-124 PET guide I-131 therapy?

Serial I-124 PET/CT scans over several days measure the time-activity curve and volume of each lesion. From those data a physicist projects the absorbed dose per unit administered I-131 activity, so the therapy activity can be tailored to deliver an intended lesion dose rather than relying on a fixed empiric activity.

What is prompt gamma coincidence contamination?

In addition to the two 511 keV annihilation photons, I-124 emits prompt gamma rays such as the 603 keV line. When a prompt gamma is detected at the same time as an annihilation photon, the scanner records a false line of response. These spurious coincidences raise apparent activity in cold regions and must be corrected to keep quantification accurate.

Does I-124 PET require a special scanner calibration?

Yes. The PET scanner's calibration factor and correction chain should be verified with an I-124 source, not assumed from F-18. Published phantom work has found the I-124 calibration factor can differ from F-18 by roughly ten percent, so an isotope-specific calibration and cross-check against the dose calibrator are important.

How long is an I-124 dosimetry protocol?

Because I-124 has a physical half-life of about 4.2 days, imaging is spread over several days — commonly scans near 24 hours and again near 96 to 120 hours after a small tracer activity — to capture uptake and clearance. The long half-life is what makes multi-day lesion dosimetry practical.

Is I-124 a therapeutic isotope?

No. I-124 is used as a diagnostic and dosimetry tracer. The therapy is delivered with I-131, whose beta particles deposit dose in tissue. I-124 predicts where and how much dose I-131 will deliver, which is why the two are often described as a theranostic pair.

Key Takeaways

I-124 is a dosimetry tracer, not a therapy. It images iodine biodistribution with PET/CT to project the I-131 absorbed dose to thyroid cancer lesions.
Its decay scheme is the whole story. A low (~22–23%) positron branch makes images count-poor, and abundant prompt gamma rays (notably 603 keV) create spurious coincidences that must be corrected.
Calibrate and correct for I-124 specifically. Calibration factors and scatter/prompt-gamma corrections do not transfer from F-18; the difference can be on the order of 10%.
The long half-life is an asset for dosimetry. A ~4.2-day half-life lets serial scans over four to five days sample the lesion time-activity curve.
Quantification discipline drives dose accuracy. Fixed time points, frozen reconstruction, recovery corrections, and a dose-calibrator cross-check are what make the projected therapy dose defensible.
Handle it under the medical-use framework. I-124 is byproduct material governed by 10 CFR Part 35 and Part 20 or the equivalent Agreement State rules.

Conclusion

I-124 is a small niche with an outsized physics lesson: it is one of the clearest cases where careless PET quantification produces confidently wrong numbers. The same decay features that make I-124 valuable — a long half-life for multi-day imaging and iodine chemistry identical to I-131 — come bundled with a low positron branch and a thicket of prompt gamma rays that bias every uncorrected measurement.

A facility that treats I-124 as "F-18 that happens to be iodine" will report inaccurate activity concentrations and, downstream, inaccurate lesion doses. A facility that calibrates for I-124, validates its prompt-gamma correction, standardizes acquisition and reconstruction, and samples the time-activity curve carefully can turn PET/CT into a genuine pre-therapy dosimetry tool — and give the treating physician a defensible basis for individualizing radioiodine therapy.

How DRPS Can Help

Diagnostic Radiation Physics Services helps PET/CT and nuclear medicine programs build quantitatively defensible imaging workflows. For an I-124 or theranostic program, this can include scanner calibration and performance verification, isotope-specific quantification review, dosimetry-protocol design, dose-calibrator setting verification, and coordination with the therapy program's radiation-safety and written-directive procedures — delivered through our PET/CT and nuclear medicine physics and medical physics consulting services.

DRPS supports facilities across our service locations, including Florida, Maryland, Virginia, Washington DC, California, Nevada, New York, Pennsylvania, New Jersey, and Delaware.

The goal is simple: measurements you can defend, and doses you can stand behind.

Related Resources

References

International Commission on Radiological Protection. ICRP Publication 107: Nuclear Decay Data for Dosimetric Calculations. Annals of the ICRP. 2008;38(3). icrp.org
Pentlow KS, Graham MC, Lambrecht RM, Cheung NK, Larson SM. Quantitative imaging of I-124 using positron emission tomography with applications to radioimmunodiagnosis and radioimmunotherapy. Medical Physics. 1991;18(3):357-366. doi:10.1118/1.596728. PubMed
Herzog H, Tellmann L, Scholten B, Coenen HH, Qaim SM. PET imaging problems with the non-standard positron emitters yttrium-86 and iodine-124. Quarterly Journal of Nuclear Medicine and Molecular Imaging. 2008;52(2):159-165. PubMed
Lubberink M, Abdul Fatah S, Brans B, Hoekstra OS, Teule GJ. The role of 124I-PET in diagnosis and treatment of thyroid carcinoma. Quarterly Journal of Nuclear Medicine and Molecular Imaging. 2008;52(1):30-36. PubMed
Wierts R, Jentzen W, Quick HH, et al. Quantitative performance evaluation of 124I PET/MRI lesion dosimetry in differentiated thyroid cancer. Physics in Medicine and Biology. 2017;63(1):015014. doi:10.1088/1361-6560/aa990b. PubMed
Jentzen W, Phaosricharoen J, Gomez B, et al. Quantitative performance of 124I PET/MR of neck lesions in thyroid cancer patients using 124I PET/CT as reference. EJNMMI Physics. 2018;5(1):13. doi:10.1186/s40658-018-0214-y. PubMed
Weber M, Binse I, Nagarajah J, Bockisch A, Herrmann K, Jentzen W. The role of 124I PET/CT lesion dosimetry in differentiated thyroid cancer. Quarterly Journal of Nuclear Medicine and Molecular Imaging. 2019;63(3):235-252. doi:10.23736/S1824-4785.19.03201-1. PubMed
U.S. Nuclear Regulatory Commission. 10 CFR Part 35: Medical Use of Byproduct Material. ecfr.gov
National Electrical Manufacturers Association. NEMA NU 2-2018: Performance Measurements of Positron Emission Tomographs (PET). nema.org
U.S. Nuclear Regulatory Commission. 10 CFR Part 20: Standards for Protection Against Radiation. ecfr.gov